Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Ceftazidime-avibactam in Pediatric Nosocomial Pneumonia
NCT04040621Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Apr 2021
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ceftazidime + avibactam in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), sponsored by Pfizer. Primary endpoints: Plasma Concentration Time Summary for Ceftazidime and Avibactam, Area Under the Plasma Concentration-Time Profile From Time 0 to 8 Hours and 8 more. Started Jun 2020; status: terminated.
02
Drugs
ceftazidime + avibactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT04040621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040621.